Athira Pharma Stock Three Year Return
| ATHA Stock | USD 0.58 0.03 5.45% |
Athira Pharma fundamentals help investors to digest information that contributes to Athira Pharma's financial success or failures. It also enables traders to predict the movement of Athira Stock. The fundamental analysis module provides a way to measure Athira Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Athira Pharma stock.
Athira | Three Year Return |
Athira Pharma Company Three Year Return Analysis
Athira Pharma's Tree Year Return shows the total annualized return generated from holding a fund or ETFs for the last three years. The return measure includes capital appreciation, losses, dividends paid, and all capital gains distributions. This return indicator is considered by many investors to be solid measures of fund mid-term performance.
More About Three Year Return | All Equity Analysis
Three Year Return | = | (Mean of Monthly Returns - 1) | X | 100% |
Athira Three Year Return Driver Correlations
Understanding the fundamental principles of building solid financial models for Athira Pharma is extremely important. It helps to project a fair market value of Athira Stock properly, considering its historical fundamentals such as Three Year Return. Since Athira Pharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Athira Pharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Athira Pharma's interrelated accounts and indicators.
Click cells to compare fundamentals
Although Three Year Fund Return indicator can give a sense of overall fund mid-term potential, it is recommended to compare fund performances against other similar funds, ETFs, or market benchmarks for the same 3 year interval.
| Competition |
Athira Return On Tangible Assets
Return On Tangible Assets |
|
Based on the latest financial disclosure, Athira Pharma has a Three Year Return of 0.0%. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Athira Three Year Return Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Athira Pharma's direct or indirect competition against its Three Year Return to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Athira Pharma could also be used in its relative valuation, which is a method of valuing Athira Pharma by comparing valuation metrics of similar companies.Athira Pharma is currently under evaluation in three year return category among its peers.
Athira Fundamentals
| Return On Equity | -0.85 | ||||
| Return On Asset | -0.48 | ||||
| Current Valuation | (45.27 M) | ||||
| Shares Outstanding | 38.67 M | ||||
| Shares Owned By Insiders | 1.95 % | ||||
| Shares Owned By Institutions | 62.13 % | ||||
| Number Of Shares Shorted | 1.81 M | ||||
| Price To Book | 0.39 X | ||||
| EBITDA | (116.7 M) | ||||
| Net Income | (117.67 M) | ||||
| Cash And Equivalents | 252.4 M | ||||
| Cash Per Share | 6.67 X | ||||
| Total Debt | 1.58 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 26.40 X | ||||
| Book Value Per Share | 3.41 X | ||||
| Cash Flow From Operations | (100.75 M) | ||||
| Short Ratio | 2.74 X | ||||
| Earnings Per Share | (2.84) X | ||||
| Target Price | 0.55 | ||||
| Number Of Employees | 65 | ||||
| Beta | 2.84 | ||||
| Market Capitalization | 22.27 M | ||||
| Total Asset | 160.25 M | ||||
| Retained Earnings | (309.21 M) | ||||
| Working Capital | 125.89 M | ||||
| Net Asset | 160.25 M |
About Athira Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Athira Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Athira Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Athira Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Athira Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Athira Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Athira Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Athira Pharma Stock:Check out Athira Pharma Piotroski F Score and Athira Pharma Altman Z Score analysis. For information on how to trade Athira Stock refer to our How to Trade Athira Stock guide.You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Athira Pharma. If investors know Athira will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Athira Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.84) | Return On Assets (0.48) | Return On Equity (0.85) |
The market value of Athira Pharma is measured differently than its book value, which is the value of Athira that is recorded on the company's balance sheet. Investors also form their own opinion of Athira Pharma's value that differs from its market value or its book value, called intrinsic value, which is Athira Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Athira Pharma's market value can be influenced by many factors that don't directly affect Athira Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Athira Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Athira Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Athira Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.